DIL Ltd. (earlier known as Duphar-Interfran Ltd.) It has built a stellar reputation for itself in the arenas of
pharmaceuticals, biotechnology, environmental solutions and other
segments including Entertainment and Health & Wellness.
On May 1st 1951, Dr. Raju incorporated ‘International Franchises
Private Limited’ a company specializing in toll manufacturing of
pharmaceutical products on behalf of overseas MNC’s.
In 1959, the company set up a manufacturing facility in Thane in its
endeavor to develop its own pharmaceutical range of products and began
negotiations with potential foreign collaborators. In 1963, the company
established financial cum technical collaborations with N.V.
Philips-Duphar, Amsterdam and The Crookes Laboratories, UK to form the
Joint Venture Crookes-Interfran Limited.
With access to an established product range and extensive R&D
facilities, the collaboration transformed Duphar-Interfran Ltd. into a
full-fledged pharmaceutical company. The product range included
internationally reputed brands “LACTO CALAMINE” Lotion and an
indigenously developed analgesic brand “CROCIN” based on Paracetamol IP
which remains a household name in India.
To further develop its association with its Research Oriented
collaborator Duphar B.V., the company changed its name to
Duphar-Interfran Ltd. in 1971 and initiated the manufacture of Vitamin
D3 and other Bulk Drugs.
This early success was merely a sign of things to come. Over the
years the company went from strength to strength and became a leading
player in the manufacture and marketing of Pharmaceuticals, Cosmetics
and Bulk Drugs with a presence all over India.
In 1976, Duphar-Interfran Ltd. was listed on the Bombay Stock Exchange
In 1980, Solvay acquired Duphar B.V. thereby becoming the Joint Venture
partner of the company. This also meant a further expansion of the
company’s healthcare product offerings in India with the product
portfolio of Kali-Chemie, Germany (an associate of Solvay).
In 1985, Dr. DVK Raju stepped down and his son Mr. Datla Vasant Kumar took over as Managing Director of the company.
To further enhance shareholder value, Mr. Datla Vasant Kumar
implemented various new initiatives to realign the business and also
made new investments which included:
Establishment of a subsidiary Fermenta Biotech Ltd. (FBL) in 1986 which
specializes in the production of nature based enzymes (catalyst) for
the production of Beta-Lactum antibiotics through the enzymatic route.
Sale of “CROCIN” and “LACTO CALAMINE” brands in 1996, to SmithKline Beecham and Piramal Healthcare Ltd. respectively.
Phasing out of Manufacturing Operations though toll manufacturing arrangements
Demerger of its Pharmaceutical division in 2002 in favour of Solvay
Pharmaceuticals and realigning the shareholding of the company ensuring
that the DVK group became a majority shareholder in Duphar-Interfran
Ltd.
Changed the name of the Company to DIL Ltd.
Licensed the Bulk Drugs Business to FBL in 2003 thereby bring the
pharmaceuticals and biotechnology businesses under one umbrella
From 2004 DIL Ltd. forayed into new business segments including:
ontract research and custom synthesis for which a subsidiary company
Research Support International Ltd. (‘RSIL’) was set up. RSIL Ltd.
later established a Joint Venture with Evotec A.G. and was subsequently
bought over by them
Created an entertainment division under the brand White Stripes;
Established a Joint Venture in the Czech Republic under the name Vasko
Gliders to manufacture wheelchairs based on a patented magnetic
levitation technology.
n 2010, the company ventured into the Health and Wellness space by
investing in a luxury healthcare brand “ZELA” in South India. In 2012,
the company entered into a real estate venture “THANE ONE”.
FINANCIALS :
Stock is trading at 1.08 times its book value
Stock is providing a good dividend yield of 3.54%.
Company has been maintaining a healthy dividend payout of 34.34%Quarterly Results Consolidated
| arration | 13-Jun | 13-Sep | 13-Dec | 14-Mar |
| Quarter | 1st Qtr | 2nd Qtr | 3rd Qtr | 4th Qtr |
| Sales | 25.96 | 28.81 | 44.48 | 39.58 |
| Operating Profit | 5.87 | 3.83 | 10.4 | 8.27 |
| Other Income | 0.05 | 0.02 | 0.03 | 0.03 |
| EBIDT | 5.92 | 3.85 | 10.43 | 8.3 |
| Interest | 1.35 | 1.32 | 1.3 | 1.33 |
| Depreciation | 2.86 | 2.39 | 2.41 | 2.17 |
| Tax | 0.49 | 0.08 | 1.64 | 1.28 |
| Net profit | 0.93 | -0.09 | 3.56 | 3.48 |
| Adjusted EPS in | 4.04 | -0.39 | 15.48 | 15.13 |
AnnualResultsConsolidated | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
No comments:
Post a Comment